Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Date:10/4/2011

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Guo, demonstrating the improved pharmacokinetics of pRNA molecules in several relevant in vivo model systems, primarily in cancer.

"The pRNA patents are a result of Kylin's and Dr. Guo's visionary efforts to borrow from nature and create novel, therapeutically superior RNA molecules," said Davis. "We continue to believe this is an entirely new intellectual property landscape in the field of RNA-based therapeutics, one that is distinct and protectable from other patents in the RNAi and antisense fields."

Following a Notice of Allowance, the process resulting in final issuance of a patent involves a number of administrative steps that are typically completed in a few months.

About Kylin Therapeutics

Kylin Therapeutics, Inc., a second-generation RNAi company, employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.

Contact: Eric Davis, Kylin Therapeutics, 919-386-9694, edavis@kylintherapeutics.com, http://www.kylintherapeutics.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Wisconsin (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses ... with reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency ...
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)...  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks ... head lice treatment salon to set up shop. But there,s ... a French bistro on E Madison Ave, and CEO ... old lice clinic, we pride ourselves on being a destination ... of the stigma associated with lice. Everyone can get lice ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring ... home or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor ...
Breaking Biology Technology:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):